NCT04028245 2026-04-15
SPARC-1
Columbia University
Phase EARLY_PHASE1 Completed
Clinical Trials
11 trialsNCT02964078 2026-04-02
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07090148 2026-03-11
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
University of Wisconsin, Madison
Phase 1 Recruiting
NCT06114940 2026-03-05
PLUTO
Jinling Hospital, China
Phase 2 Terminated
NCT06255223 2025-09-03
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Jinling Hospital, China
Phase 2 Recruiting
NCT03815942 2025-06-25
ADVANCE
University of Oxford
Phase 1/2 Terminated
NCT04802876 2025-03-21
ACROPOLI
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT03991130 2025-02-06
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
Phase 2 Terminated
NCT04430036 2024-04-04
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT04385654 2020-05-13
Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
West China Hospital
Phase 2 Unknown
NCT01420965 2019-07-10
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Augusta University
Phase 2 Terminated